Circulating tumor cells enumeration and characterization in patients with lung cancer treated with immunotherapy.

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Circulating Tumor Cell PD-L1 and Peripheral Blood CD8+ T-Cell PD-1 as Dual Liquid Biopsy Biomarkers for Immunotherapy Outcomes in Advanced Non–Small Cell Lung Cancer: A Retrospective Study2026
2. 2The clinical application of circulating tumor cells (CTCs) for immunotherapy in advanced pancreatic cancer.2024 · 1 citations
3. 3Prognostic and Predict Value of Peripheral Blood Circulating Tumor Cells Programmed Death‐Ligand 1 Expression and F‐18‐Fluorodeoxyglucose Metabolic Parameters in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors2026
4. 4PD-L1-positive circulating tumor cells associate with tumor malignancy and impaired circulating immunity in patients with gastrointestinal tumors2026
5. 5PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with hepatocellular carcinoma receiving PD-(L)1 blockade and targeted therapy2026 · 2 citations